Hiring in life sciences? Share your open positions with our professional community. Read more Close

Advertisement

Prolonged survival of 3 dogs with Prototheca bovis infection treated with posaconazole.

Created on 25 Aug 2026

Authors

Kathrin F A Langner, Ammie Higgins, Margie Roser, Troy A Bunn, Amy Lam, Angelika Proskurnicka, Tomasz Jagielski, Richard Malik

Published in

Journal of veterinary internal medicine. Volume 40. Issue 4. Jul 01, 2026.

Abstract

Primary enteric or disseminated infections with Prototheca bovis in dogs typically are associated with short survival times despite treatment. We describe the extended clinical course of 3 dogs diagnosed with enteric P. bovis infection treated with antifungal therapy incorporating posaconazole. One dog was alive 45 months after starting treatment, exhibiting only mild, intermittent diarrhea and no detectable algae on rectal cytology. This dog also received SC amphotericin B (AMB) infusions during the first month after diagnosis. The second dog, managed exclusively with posaconazole, was alive after 39 months with moderate mixed-bowel diarrhea and ongoing P. bovis shedding but without clinical signs of dissemination. The third dog survived 21 months before death because of central nervous system dissemination; additional treatments included itraconazole, AMB, terbinafine, and immunotherapy using an autologous vaccine. Posaconazole was well tolerated in all dogs and can be considered a therapeutic option for dogs with enteric protothecosis.

PMID:
42636342
Bibliographic data and abstract were imported from PubMed on 25 Aug 2026.

Read full publication at:
Please sign in to see all details.

Advertisement

Stats

  • Community rating n/a 0 votes
  • Reviewers' rating n/a 0 votes
  • Your rating

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

  • Recommendations n/a n/a positive of 0 vote(s)
  • Views 5
  • Comments 0

Recommended by

  • No recommendations yet.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.

Advertisement